Search For a Provider Facebook Twitter Instagram YouTube ES View the Patient Toolkit


Flibanserin Update

Jun 16, 2015

Flibanserin UpdateThe U.S. Food and Drug Administration (FDA) could be on its way to approving the female sex health drug flibanserin, if it follows the recommendations made by an advisory panel last week.

Flibanserin is intended to treat hypoactive sexual desire disorder (HSDD). Women with HSDD have a persistent lack of sexual interest that brings them great distress.


Is FDA approval for female sex health drug flibanserin coming? (Click to tweet)


It’s normal for women to have a low sex drive from time to time. What makes HSDD different is that it’s chronic and can’t be explained by another health condition or a medication side effect.

Flibanserin has been up for FDA approval – and rejected – twice already because of concerns over safety and effectiveness. The most recent rejection occurred in 2013. At that time, the FDA was not convinced that the benefits of flibanserin outweighed the risks. It was unclear how flibanserin and alcohol would interact. And some experts worried that side effects like sleepiness could lead to accidental injuries.


1 2 3 Next » (page 1 of 3)